News

Female Viagra may be on the way from drug company BioSante

Pin it

According to pharmaceutical company BioSante, their not-yet-approved female-libido drug LibiGel doesn't cause cancer or heart attacks. This apparently has been a matter of some dispute, not with specific regard to LibiGel, but to hormone-treatment medications in general; in the past decade, the FDA has rejected on safety grounds several applications for testosterone creams, patches, and ointments said to boost female libido. (Testosterone injections also apparently reduce empathy. Wins all around here.)

Obviously there're massive profits in store for whichever drug company develops an at least semi-effective "female Viagra" that doesn't cause too much cancer, cardiovascular disaster, or vaginal inversion. This one may hit the market as soon as next year, assuming tests continue to be favorable. Whether female-libido drugs are really necessary remains, of course, an open question.